Helicobacter pylori eradication one-week triple therapy with esomeprazole versus lansoprazole, amoxicillin and clarithromycin: a randomized, open-label, non-inferiority trial.

Helicobacter pylori eradication one-week triple therapy with esomeprazole versus lansoprazole, amoxicillin and clarithromycin: a randomized, open-label, non-inferiority trial. - Helicobacter pylori eradication one-week triple therapy with esomeprazole, amoxicillin and clarithromycin

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007733

Enrollment

260

Registered

2012-04-13

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Esomeprazole 20mg, AMPC 750mg, CAM 400mg, twice a day for 7days Lansoprazole 10mg, AMPC 750mg, CAM 400mg, twice a day for 7days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with past history of peptic ulcer, gastric MALT lymphoma, Idiopathic thrombocytopenic purpura, and early gastric cancer treated by endoscopic resection, related to H.pylori infection

Exclusion criteria

Exclusion criteria: Past history of allergy for the drugs used in this study. Past history of taking eradication therapy. Past history of gastrectomy. Gastric cancer patients, pregnancy or lactation. Severe renal dysfunction, Blood disease, Infectious Mononucleosis Patients who are disqualified for the study by their physicians

Design outcomes

Primary

Measure	Time frame
Non-inferiority trial of the eradication rate of the two regimens, esomeprazole versus lansoprazole based triple therapy	—

Secondary

Measure	Time frame
Comparison between adverse event rates in patients with esomeprazole versus lansoprazole based triple therapy	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026